The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs - 'favipiravir' and 'phytopharmaceutical' - to combat coronavirus.Favipiravir is a drug which is commonly used in Japan, China and some other countries, to treat influenza that has a very broad spectrum of RNA polymerase.